Committee Views Fampridine-SR as Safe, Effective and Clinically
Meaningful for Improving Walking in People with Multiple Sclerosis
Conference Call Scheduled for Thursday, October 15 at 8:00 a.m.
HAWTHORNE, N.Y.--(BUSINESS WIRE)--Oct. 14, 2009--
Acorda Therapeutics, Inc. (Nasdaq: ACOR)
today announced the U.S. Food and Drug Administration (FDA) Peripheral
and Central Nervous System Drugs (PCNSD) Advisory Committee voted 12 to
1 that clinical data on Fampridine-SR 10 mg twice daily demonstrated
substantial evidence of effectiveness as a treatment to improve walking
in people with multiple sclerosis (MS) and voted 10 to 2 (1 abstention)
that it is clinically meaningful and can be safe for use.
“We are pleased with the outcome of today’s Advisory Committee meeting.
People with MS have an urgent need for therapies to improve their
walking, which is essential to conducting their activities of daily
life. If approved, Fampridine-SR would be the first medicine to improve
walking in people with MS,” said Ron Cohen, M.D., Acorda Therapeutics
President and CEO. “This Advisory Committee meeting is an important
milestone in the development of Fampridine-SR, and we look forward to
working with the FDA as it completes its review of Acorda’s New Drug
The Committee also recommended by a vote of 12 to 1 that Acorda be
required to evaluate the effects of doses lower than 10 mg twice daily,
but by a 10 to 2 vote (1 abstention) that these studies not be required
prior to approval.
At the request of the FDA, the Committee discussed possible conditions
for use, including for patients with renal impairment or history of
seizure. Acorda has proposed a Risk Evaluation and Mitigation Strategy
(REMS) program, which could include healthcare professional and patient
education around appropriate use of Fampridine-SR.
The FDA seeks the advice of an advisory committee such as the PCNSD when
evaluating a potential new treatment, but is not required to follow its
recommendation. The current Fampridine-SR Prescription Drug User Fee Act
(PDUFA) date set by the FDA is October 22, 2009; the PDUFA date is the
target date for the FDA to complete its review of Fampridine-SR.
Acorda will hold a conference call and audio webcast on Thursday,
October 15, 2009 at 8:00 a.m. ET to discuss the outcome of the Advisory
Committee meeting. To participate in the conference call, please dial
866-700-6979 (domestic) or 617-213-8836 (international) and
reference the access code 85689772. The presentation will be available
via a live audio webcast at:
A replay of the call will be available from 11:00 a.m. ET on October 15,
2009 until midnight on November 14, 2009. To access the replay, please
dial 888-286-8010 (domestic) or 617-801-6888 (international) and
reference the access code 45457470. The archived webcast will be
available for 30 days in the Investor Relations section of the Acorda
website at http://www.acorda.com.
Fampridine-SR is a sustained-release tablet formulation of the
investigational drug fampridine (4-aminopyridine or 4-AP). In laboratory
studies, fampridine has been found to improve impulse conduction in
nerve fibers in which the insulating layer, called myelin, has been
damaged. Fampridine-SR is being developed by Acorda Therapeutics and
manufactured by Elan Corporation plc.
Multiple sclerosis is a chronic, usually progressive disease in which
the immune system attacks and degrades the function of nerve fibers in
the brain and spinal cord. More than 400,000 Americans have MS, most
between the ages of 20 and 50, with women affected two to three times
more than men. Worldwide, MS may affect 2.5 million individuals.
Research indicates 64%-85% of people with MS have difficulty walking,
and 70% report walking to be the most challenging aspect of their MS.
Within 15 years of an MS diagnosis, 50 percent of patients often require
assistance walking and, in later stages, up to a third of patients are
unable to walk.
Acorda Therapeutics is a biotechnology company developing therapies for
spinal cord injury, multiple sclerosis and related nervous system
disorders. The Company's marketed products include Zanaflex Capsules®
(tizanidine hydrochloride), a short-acting drug for the management of
spasticity. The Company's pipeline includes a number of products in
development for the treatment, regeneration and repair of the spinal
cord and brain.
This press release includes forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995. All
statements, other than statements of historical facts, regarding
management's expectations, beliefs, goals, plans or prospects should be
considered forward-looking. These statements are subject to risks and
uncertainties that could cause actual results to differ materially,
including delays in obtaining or failure to obtain FDA approval of
Fampridine-SR, the risk of unfavorable results from future studies of
Fampridine-SR, Acorda Therapeutics' ability to successfully market and
sell Fampridine-SR, if approved, and Zanaflex Capsules, competition,
failure to protect its intellectual property or to defend against the
intellectual property claims of others, the ability to obtain additional
financing to support Acorda Therapeutics' operations, and unfavorable
results from its preclinical programs. These and other risks are
described in greater detail in Acorda Therapeutics' filings with the
Securities and Exchange Commission. Acorda Therapeutics may not actually
achieve the goals or plans described in its forward-looking statements,
and investors should not place undue reliance on these statements.
Acorda Therapeutics disclaims any intent or obligation to update any
forward-looking statements as a result of developments occurring after
the date of this press release.
Source: Acorda Therapeutics, Inc.
Jeff Macdonald, 914-347-4300 ext. 232